HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 280, Issue 44, 36784-36791, November 4, 2005

This Article Full Text Full Text (PDF) All Versions of this Article: 280/44/36784    most recent M506462200v2 M506462200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lin, C. Articles by Kwong, A. D. Search for Related Content PubMed PubMed Citation Articles by Lin, C. Articles by Kwong, A. D. Social Bookmarking                      What's this?

In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061^*

From the Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139

VX-950 is a potent, small molecule, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3·4A serine protease and has recently been shown to possess antiviral activity in a phase I trial in patients chronically infected with genotype 1 HCV. In a previous study, we described in vitro resistance mutations against either VX-950 or another HCV NS3·4A protease inhibitor, BILN 2061 (Lin, C., Lin, K., Luong, Y.-P., Rao, B. G., Wei, Y.-Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., Cottrell, K. M., Perni, R. B., Gates, C. A., and Kwong, A. D. (2004) J. Biol. Chem. 279, 17508-17514). Single amino acid substitutions that conferred drug resistance (distinct for either inhibitor) were identified in the HCV NS3 serine protease domain. The dominant VX-950-resistant mutant (A156S) remains sensitive to BILN 2061. The major BILN 2061-resistant mutants (D168V and D168A) are fully susceptible to VX-950. Modeling analysis suggested that there are different mechanisms of resistance for these mutations induced by VX-950 or BILN 2061. In this study, we identified mutants that are cross-resistant to both HCV protease inhibitors. The cross-resistance conferred by substitution of Ala¹⁵⁶ with either Val or Thr was confirmed by characterization of the purified enzymes and reconstituted replicon cells containing the single amino acid substitution A156V or A156T. Both cross-resistance mutations (A156V and A156T) displayed significantly diminished fitness (or replication capacity) in a transient replicon cell system.

Received for publication, June 14, 2005 , and in revised form, July 20, 2005.

^* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Dept. of Infectious Diseases Biology, Vertex Pharmaceuticals Inc., 130 Waverly St., Cambridge, MA 02139. Tel.: 617-444-6202; Fax: 617-444-6210; E-mail: chao_lin{at}vrtx.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Paeshuyse, I. Vliegen, L. Coelmont, P. Leyssen, O. Tabarrini, P. Herdewijn, H. Mittendorfer, J. Easmon, V. Cecchetti, R. Bartenschlager, et al. Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3433 - 3437. [Abstract] [Full Text] [PDF]

				M. F. McCown, S. Rajyaguru, S. Le Pogam, S. Ali, W.-R. Jiang, H. Kang, J. Symons, N. Cammack, and I. Najera The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1604 - 1612. [Abstract] [Full Text] [PDF]

				D. L. Wyles, K. A. Kaihara, and R. T. Schooley Synergy of a Hepatitis C Virus (HCV) NS4A Antagonist in Combination with HCV Protease and Polymerase Inhibitors Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1862 - 1864. [Abstract] [Full Text] [PDF]

				Y. He, M. S. King, D. J. Kempf, L. Lu, H. B. Lim, P. Krishnan, W. Kati, T. Middleton, and A. Molla Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1101 - 1110. [Abstract] [Full Text] [PDF]

				G. Cheng, A. Montero, P. Gastaminza, C. Whitten-Bauer, S. F. Wieland, M. Isogawa, B. Fredericksen, S. Selvarajah, P. A. Gallay, M. R. Ghadiri, et al. A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro PNAS, February 26, 2008; 105(8): 3088 - 3093. [Abstract] [Full Text] [PDF]

				S. T. Shi, K. J. Herlihy, J. P. Graham, S. A. Fuhrman, C. Doan, H. Parge, M. Hickey, J. Gao, X. Yu, F. Chau, et al. In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase Antimicrob. Agents Chemother., February 1, 2008; 52(2): 675 - 683. [Abstract] [Full Text] [PDF]

				Y. Zhou, D. J. Bartels, B. L. Hanzelka, U. Muh, Y. Wei, H.-M. Chu, A. M. Tigges, D. L. Brennan, B. G. Rao, L. Swenson, et al. Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease Antimicrob. Agents Chemother., January 1, 2008; 52(1): 110 - 120. [Abstract] [Full Text] [PDF]

				R. K. F. Beran, V. Serebrov, and A. M. Pyle The Serine Protease Domain of Hepatitis C Viral NS3 Activates RNA Helicase Activity by Promoting the Binding of RNA Substrate J. Biol. Chem., November 30, 2007; 282(48): 34913 - 34920. [Abstract] [Full Text] [PDF]

				Y. Zhou, U. Muh, B. L. Hanzelka, D. J. Bartels, Y. Wei, B. G. Rao, D. L. Brennan, A. M. Tigges, L. Swenson, A. D. Kwong, et al. Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants: SENSITIVITY TO TELAPREVIR (VX-950) AND INTERFERON {alpha} J. Biol. Chem., August 3, 2007; 282(31): 22619 - 22628. [Abstract] [Full Text] [PDF]

				D. L. Wyles, K. A. Kaihara, F. Vaida, and R. T. Schooley Synergy of Small Molecular Inhibitors of Hepatitis C Virus Replication Directed at Multiple Viral Targets J. Virol., March 15, 2007; 81(6): 3005 - 3008. [Abstract] [Full Text] [PDF]

				A. Wohnsland, W. P. Hofmann, and C. Sarrazin Viral Determinants of Resistance to Treatment in Patients with Hepatitis C Clin. Microbiol. Rev., January 1, 2007; 20(1): 23 - 38. [Abstract] [Full Text] [PDF]

				R. Liu, K. Abid, J. Pichardo, V. Pazienza, P. Ingravallo, R. Kong, S. Agrawal, S. Bogen, A. Saksena, K.-C. Cheng, et al. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease J. Antimicrob. Chemother., January 1, 2007; 59(1): 51 - 58. [Abstract] [Full Text] [PDF]

				H. Dutartre, C. Bussetta, J. Boretto, and B. Canard General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide Analogues Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4161 - 4169. [Abstract] [Full Text] [PDF]

				K. Lin, R. B. Perni, A. D. Kwong, and C. Lin VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1813 - 1822. [Abstract] [Full Text] [PDF]

				R. B. Perni, S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, et al. Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease Antimicrob. Agents Chemother., March 1, 2006; 50(3): 899 - 909. [Abstract] [Full Text] [PDF]